Business

According to North Carolina-based Cornerstone Therapeutics, Chiesi Farmaceutici has offered to purchase shares of Cornerstone's common stock for between $6.40 and $6.70 per share, to take the company private. Chiesi already owns approximately 60% of the outstanding shares of Cornerstone's common stock. No decision has been made by Cornerstone's board of directors at … [Read more...] about Chiesi looks to acquire Cornerstone Therapeutics

CRO Quintiles says that it has filed a registration statement with the US. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of an undisclosed number of shares of common stock. The company says that it plans to use the proceeds to pay down debt and "for general corporate purposes." Quintiles previously went public in 1994, then went private … [Read more...] about Quintiles to go public again

Discovery Laboratories says that Deerfield Management Company will provide the company up to $30 million in the form of a secured loan facility. Discovery Labs will use the money for development and commercialization of its Surfaxin lucinactant for the prevention of respiratory distress syndrome (RDS) in infants and Aerosurf aerosolized surfactant for the treatment of … [Read more...] about Discovery Labs gets $30 million for development of respiratory distress syndrome therapies

MeadWestvaco has announced a $7.5 million expansion of its pharmaceutical manufacturing Centre of Excellence in Hemer, Germany, an expansion the company attributes largely to growth in the preservative-free nasal product market. According to the company, the project includes additional capacity in clean room molding and assembly. MWV offers a number of spray pumps for … [Read more...] about MeadWestvaco expands preservative-free product manufacturing capacity

The US Patent and Trade Office (USPTO) has granted Mystic Pharmaceuticals US Patent No. 8,377,009, according to the company. The patent, titled “Intranasal Cartridge Devices,” covers technology for a delivery system based on Mystic's unit dose delivery platforms for liquid or dry intranasal formulations of drugs and biologics. Mystic President and CEO Timothy … [Read more...] about Mystic gets US patent for intranasal delivery technology

Allergan will acquire Levadex inhaled dihydroergotamine developer MAP Pharmaceuticals for $25 per share. The two companies entered into an agreement to co-promote Levadex in January 2011, and MAP submitted an NDA for the product later that year. The FDA issued a complete response letter for Levadex in March 2012, and MAP resubmitted the NDA in October of that year. … [Read more...] about Allergan to acquire MAP Pharmaceuticals

Catalent Pharma Solutions has announced that it will invest $20 million to enhance pMDI clinical and commercial supply capabilities, along with other enhancements, at its Inhalation Center of Excellence in Research Triangle Park (RTP), North Carolina. The company offers a range of development and manufacturing services for inhaled products and says that it also … [Read more...] about Catalent to invest $20 million to expand inhalation capabilities

The Bluetooth Special Interest Group (SIG) has named Asthmapolis a finalist in the "Breakthrough Products" category for the Bluetooth Breakthrough Awards. The FDA granted 510(k) clearance to the Asthmapolis inhaler sensor system and mobile app in July 2012. When attached to the top of an MDI canister, the sensor records accelerometer and GPS data, which it transmits … [Read more...] about Asthmapolis named a finalist for Bluetooth Breakthrough Awards